Kindstar Globalgene Technology, Inc. (HK:9960)
:9960
Want to see HK:9960 full AI Analyst Report?
9960 Stock Chart & Stats
HK$1.17
HK$0.05(4.55%)
At close: 4:00 PM EST
HK$1.17
HK$0.05(4.55%)
Day’s Range― - ―
52-Week RangeHK$1.03 - HK$1.75
Previous CloseN/A
Volume114.00K
Average Volume (3M)956.95K
Market Cap
HK$1.16B
Enterprise ValueHK$1.04B
Total Cash (Recent Filing)HK$1.56B
Total Debt (Recent Filing)HK$438.12M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,041,309,900
10 Day Avg. Volume603,200
30 Day Avg. Volume956,950
Financial Highlights & Ratios
PEG Ratio-6.54
Price to Book (P/B)0.37
Price to Sales (P/S)1.07
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetKindstar’s low debt-to-equity and sizable equity base provide durable financial resilience, reducing bankruptcy and refinancing risk. This capital conservatism supports discretionary investments, M&A optionality, and the ability to withstand industry headwinds without forcing dilutive financing.
Turnaround To Positive Cash FlowThe 2025 swing to positive operating and free cash flow demonstrates the business can generate internal funding for operations and reinvestment. If maintained, this improves self-funding capacity, lowers dependency on external capital, and strengthens medium-term financial flexibility.
Healthy Gross MarginA ~44% gross margin implies strong core service economics in specialized diagnostics. Durable gross profitability provides room to absorb SG&A and R&D investment, supports pricing power in niche tests, and aids margin recovery if revenue stabilizes or scale is restored.
Bears Say
Sustained Revenue ContractionThree consecutive years of revenue decline indicate persistent demand or pricing challenges in core markets. Reduced top-line scale pressures fixed-cost absorption, hinders investment ROI, and makes operational leverage harder to achieve, constraining durable earnings recovery prospects.
Continued Net Losses And Negative ReturnsOngoing net losses and negative ROE show the firm is not generating acceptable returns on capital. This undermines shareholder value creation, limits retained-earnings funding for growth, and raises pressure on management to restore profitability sustainably.
Volatile Cash GenerationHistoric multi-year negative free cash flow followed by a single-year improvement signals unreliable cash conversion. Such volatility hampers multi-year planning, increases reliance on financing in downturns, and raises execution risk that 2025 cash gains may not persist.
Kindstar Globalgene Technology, Inc. News
9960 FAQ
What was Kindstar Globalgene Technology, Inc.’s price range in the past 12 months?
Kindstar Globalgene Technology, Inc. lowest stock price was HK$1.03 and its highest was HK$1.75 in the past 12 months.
What is Kindstar Globalgene Technology, Inc.’s market cap?
Kindstar Globalgene Technology, Inc.’s market cap is HK$1.16B.
When is Kindstar Globalgene Technology, Inc.’s upcoming earnings report date?
Kindstar Globalgene Technology, Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 103 days.
How were Kindstar Globalgene Technology, Inc.’s earnings last quarter?
Kindstar Globalgene Technology, Inc. released its earnings results on Mar 30, 2026. The company reported -HK$0.025 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.025.
Is Kindstar Globalgene Technology, Inc. overvalued?
According to Wall Street analysts Kindstar Globalgene Technology, Inc.’s price is currently Overvalued.
Does Kindstar Globalgene Technology, Inc. pay dividends?
Kindstar Globalgene Technology, Inc. pays a Annually dividend of HK$0.024 which represents an annual dividend yield of 2.02%. See more information on Kindstar Globalgene Technology, Inc. dividends here
What is Kindstar Globalgene Technology, Inc.’s EPS estimate?
Kindstar Globalgene Technology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kindstar Globalgene Technology, Inc. have?
Kindstar Globalgene Technology, Inc. has 1,041,309,900 shares outstanding.
What happened to Kindstar Globalgene Technology, Inc.’s price movement after its last earnings report?
Kindstar Globalgene Technology, Inc. reported an EPS of -HK$0.025 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.67%.
Which hedge fund is a major shareholder of Kindstar Globalgene Technology, Inc.?
Currently, no hedge funds are holding shares in HK:9960
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kindstar Globalgene Technology, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.75%
12-Months-Change
Fundamentals
Return on Equity
-2.11%
Trailing 12-Months
Asset Growth
4.10%
Trailing 12-Months
Company Description
Kindstar Globalgene Technology, Inc.
Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and technology institutions, specialty and general hospitals, and pharmaceutical companies. The company's lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research laboratories. It provides tests in blood, tumor, and genetics; and cardiovascular, cerebrovascular, infectious, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics, and other specialties. The company was founded in 2003 and is headquartered in in Wuhan, China.
Technical Analysis
Jinxin Fertility Group Ltd.
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
JD Health International, Inc.
―
Concord Healthcare Group Co., Ltd. Class H
―
Options Prices
Currently, No data available
---